
    
      The study consists of a 24-week double-blind, placebo control period, a 28-week open-label
      extension period and an 8-week follow-up period. Eligible participants will be randomized to
      placebo or nipocalimab (2 dose levels) during the double-blind period and nipocalimab (2 dose
      levels) during the open-label extension period.
    
  